Staphylococcal Infections

Infectious Diseases of the Fetus and Newborn Infant

Volumn , Issue , 2011, Pages 489-515

  Nizet, Victor ^a   Bradley, John S ^b  

^a Department of Clinical Research   (United States)

^b IWK HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882534820     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-6400-8.00014-6     Document Type: Chapter

References (346)

1. Fox T. Epidemic pemphigus of newly born (impetigo contagiosa et bullosa neonatorum). Lancet 1935, 1:1323.
2. Rulison E.T. Control of impetigo neonatorum: advisability of a radical departure in obstetrical care. JAMA 1929, 93:903.
3. Eichenwald H.F., Kotsevalov O., Fasso L.A. The "cloud baby": an example of bacterial-viral interaction. Am. J. Dis. Child. 1960, 100:161-173.
4. Dixon R.E., et al. Staphylococcal disease outbreaks in hospital nurseries in the United States-December 1971 through March 1972. Pediatrics 1973, 51:413.
5. Gaynes R.P., et al. Nosocomial infections among neonates in high-risk nurseries in the United States. National Nosocomial Infections Surveillance System. Pediatrics 1996, 98:357.
6. Stoll B.J., et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002, 110:285-291.
7. Bizzarro M.J., et al. Seventy-five years of neonatal sepsis at Yale: 1928-2003. Pediatrics 2005, 116:595-602.
8. Shinefield H.R., et al. Bacterial interference: its effect on nursery-acquired infection with Staphylococcus aureus. I. Preliminary observations. Am. J. Dis. Child. 1963, 105:646.
9. Fairchild J.P., et al. Flora of the umbilical stump: 2479 cultures. J. Pediatr. 1958, 53:538.
10. Gillespie W.A., Simpson K., Tozer R.C. Staphylococcal infection in a maternity hospital: epidemiology and control. Lancet 1958, 2:1075.
11. Hurst V. Transmission of hospital staphylococci among newborn infants. II. Colonization of the skin and mucous membranes of the infants. Pediatrics 1960, 25:204.
12. Schaffer T.E., et al. Staphylococcal infections in newborn infants. II. Report of 19 epidemics caused by an identical strain of Staphylococcus pyogenes. Am. J. Public Health 1957, 47:990.
13. Wolinsky E., Lipsitz P.J., Mortimer E.A. Acquisition of staphylococci by newborns: direct versus indirect transmission. Lancet 1960, 2:620.
14. Shinefield H.R., et al. Bacterial interference: its effect on nursery-acquired infection with Staphylococcus aureus. II. The Ohio epidemic. Am. J. Dis. Child. 1963, 105:655.
15. Hare R., Thomas C.G.A. The transmission of Staphylococcus aureus. BMJ 1956, 2:840.
16. Ridely M. Perineal carriage of Staphylococcus aureus. BMJ 1959, 1:270.
17. Acton D.S., et al. Intestinal carriage of Staphylococcus aureus. How does its frequency compare with that of nasal carriage and what is its clinical impact?. Eur. J. Clin. Microbiol. Infect. Dis. 2009, 28:115-127.
18. Thompson R.L., Cabezudo I., Wenzel R.P. Epidemiology of nosocomial infections caused by methicillin-resistant Staphylococcus aureus. Ann. Intern. Med. 1982, 97:309.
19. Hiramatsu K., et al. The emergence and evolution of methicillin-resistant Staphylococcus aureus. Trends Microbiol. 2001, 9:486.
20. Boyce J.M. Methicillin-resistant Staphylococcus aureus: detection, epidemiology, and control measures. Infect. Dis. Clin. North Am. 1989, 3:901.
21. Salgado C.D., Farr B.M., Calfee D.P. Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors. Clin. Infect. Dis. 2003, 36:131.
22. Eady E.A., Cove J.H. Staphylococcal resistance revisited: community-acquired methicillin resistant Staphylococcus aureus-an emerging problem for the management of skin and soft tissue infections. Curr. Opin. Infect. Dis. 2003, 16:103.
23. Carey A.J., et al. The epidemiology of methicillin-susceptible and methicillin-resistant Staphylococcus aureus in a neonatal intensive care unit, 2000-2007. J. Perinatol. 2009, 30:135-139.
24. Gould I.M., et al. Report of a hospital neonatal unit outbreak of community-associated methicillin-resistant Staphylococcus aureus. Epidemiol. Infect. 2009, 137:1242-1248.
25. McAdams R.M., et al. Spread of methicillin-resistant Staphylococcus aureus USA300 in a neonatal intensive care unit. Pediatr. Int. 2008, 50:810-815.
26. Community-associated methicillin-resistant Staphylococcus aureus infection among healthy newborns-Chicago and Los Angeles County, 2004. MMWR Morb. Mortal. Wkly Rep. 2006, 55:329-332.
27. Saiman L., et al. Molecular epidemiology of staphylococcal scalded skin syndrome in premature infants. Pediatr. Infect. Dis. J. 1998, 17:329.
28. Enright M.C., et al. Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus. J. Clin. Microbiol. 2000, 38:1008.
29. Diep B.A., Perdreau-Remington F., Sensabaugh G.F. Clonal characterization of Staphylococcus aureus by multilocus restriction fragment typing, a rapid screening approach for molecular epidemiology. J. Clin. Microbiol. 2003, 41:4559.
30. Goldmann D.A. Bacterial colonization and infection in the neonate. Am. J. Med. 1981, 70:417.
31. Simpson R.A., et al. Colonization by gentamicin-resistant Staphylococcus epidermidis in a special care baby unit. J. Hosp. Infect. 1986, 7:108.
32. Hall S.L., et al. Evaluation of coagulase-negative staphylococcal isolates from serial nasopharyngeal cultures of premature infants. Diagn. Microbiol. Infect. Dis. 1990, 13:17.
33. Patrick C.H., et al. Relatedness of strains of methicillin-resistant coagulase-negative Staphylococcus colonizing hospital personnel and producing bacteremias in a neonatal intensive care unit. Pediatr. Infect. Dis. J. 1992, 11:935.
34. D'Angio C.T., et al. Surface colonization with coagulase-negative staphylococci in premature neonates. J. Pediatr. 1989, 114:1029.
35. Freeman J., et al. Association of intravenous lipid emulsion and coagulase negative staphylococcal bacteremia in neonatal intensive care units. N. Engl. J. Med. 1990, 323:301.
36. Kloos W. Taxonomy and Systemics of Staphylococci Indigenous to Humans 1997, Churchill Livingstone, New York.
37. Parker M.T., Roundtree P.M. Report (1966B1970) of the Subcommittee on Phage Typing of Staphylococci to the International Committee on Nomenclature of Bacteria. Int. J. Syst. Bacteriol. 1971, 21:167.
38. Prevost G., Jaulhoc B., Piedmont Y. DNA fingerprinting of pulsed-field gel electrophoresis is more effective than ribotyping in distinguishing among methicillin-resistant Staphylococcus aureus isolates. J. Clin. Microbiol. 1992, 30:967.
39. Tenover F.C., et al. Comparison of traditional and molecular methods of typing isolates of Staphylococcus aureus. J. Clin. Microbiol. 1994, 32:407.
40. Giesbrecht P., Wecke J., Reinicke B. On the morphogenesis of the cell wall of staphylococci. Int. Rev. Cytol. 1976, 44:225-318.
41. Braddiley J., et al. The wall composition of micrococci. J. Gen. Microbiol. 1968, 54:393.
42. Labischinski H. Consequences of interaction of β-lactam antibiotics with penicillin binding proteins from sensitive and resistant Staphylococcus aureus strains. Med. Microbiol. Immunol. (Berl.) 1992, 181:241.
43. Juergens W.G., Sanderson A.R., Strominger J.L. Chemical basis for the immunological specificity of a strain of Staphylococcus aureus. Bull. Soc. Chim. Biol. (Paris) 1960, 42:110.
44. Lee J.C., Pier G.B. Vaccine-based Strategies for Prevention of Staphylococcal Diseases 1997, Churchill Livingstone, New York.
45. Verburgh H.A., et al. Antibodies to cell wall peptidoglycan of Staphylococcus aureus in patients with serious staphylococcal infections. J. Infect. Dis. 1981, 144:1.
46. Fischetti V.A., Pancholi V., Schneewind O. Conservation of a hexapeptide sequence in the anchor region of surface proteins from gram-positive cocci. Mol. Microbiol. 1990, 4:1603.
47. Mazmanian S.K., Ton-That H., Schneewind O. Sortase-catalysed anchoring of surface proteins to the cell wall of Staphylococcus aureus. Mol. Microbiol. 2001, 40:1049.
48. Foster T.J., Hook M. Surface protein adhesins of Staphylococcus aureus. Trends Microbiol. 1998, 6:484-488.
49. O'Riordan K., Lee J.C. Staphylococcus aureus capsular polysaccharides. Clin. Microbiol. Rev. 2004, 17:218-234.
50. Moreau M., et al. Structure of the type 5 capsular polysaccharide of Staphylococcus aureus. Carbohydr. Res. 1990, 201:285-297.
51. Fournier J.M., Vann W.F., Karakawa W.W. Purification and characterization of Staphylococcus aureus type 8 capsular polysaccharide. Infect. Immun. 1984, 45:87-93.
52. von Eiff C., Peters G., Becker K. The small colony variant (SCV) concept-the role of staphylococcal SCVs in persistent infections. Injury 2006, 37(Suppl. 2):S26-S33.
53. Proctor R.A., Balwit J.M., Vesga O. Variant subpopulations of Staphylococcus aureus as cause of persistent and recurrent infections. Infect. Agents Dis. 1994, 3:302-312.
54. Baba T., et al. Genome and virulence determinants of high virulence community-acquired MRSA. Lancet 2002, 359:1819.
55. Kuroda M., et al. Whole genome sequencing of methicillin-resistant Staphylococcus aureus. Lancet 2001, 357:1225.
56. Holden M.T., et al. Complete genomes of two clinical Staphylococcus aureus strains: evidence for the rapid evolution of virulence and drug resistance. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:9786-9791.
57. Diep B.A., et al. Complete genome sequence of USA300, an epidemic clone of community-acquired methicillin-resistant Staphylococcus aureus. Lancet 2006, 367:731-739.
58. Pfaller M.A., Herwaldt L.A. Laboratory, clinical and epidemiological aspects of coagulase-negative staphylococci. Clin. Microbiol. Rev. 1988, 1:281.
59. Wu F., Della-Latta P. Molecular typing strategies. Semin. Perinatol. 2002, 26:357.
60. Zhang Y.Q., et al. Genome-based analysis of virulence genes in a non-biofilm-forming Staphylococcus epidermidis strain (ATCC 12228). Mol. Microbiol. 2003, 49:1577.
61. Ni Eidhin D., et al. Clumping factor B (ClfB), a new surface-located fibrinogen-binding adhesin of Staphylococcus aureus. Mol. Microbiol. 1998, 30:245-257.
62. O'Connell D.P., et al. The fibrinogen-binding MSCRAMM (clumping factor) of Staphylococcus aureus has a Ca2+-dependent inhibitory site. J. Biol. Chem. 1998, 273:6821-6829.
63. Fowler T., et al. Cellular invasion by Staphylococcus aureus involves a fibronectin bridge between the bacterial fibronectin-binding MSCRAMMs and host cell beta1 integrins. Eur. J. Cell. Biol. 2000, 79:672-679.
64. Moreillon P., et al. Role of Staphylococcus aureus coagulase and clumping factor in pathogenesis of experimental endocarditis. Infect. Immun. 1995, 63:4738-4743.
65. Patti J.M., et al. Molecular characterization and expression of a gene encoding a Staphylococcus aureus collagen adhesin. J. Biol. Chem. 1992, 267:4766-4772.
66. Patti J.M., et al. The Staphylococcus aureus collagen adhesin is a virulence determinant in experimental septic arthritis. Infect. Immun. 1994, 62:152-161.
67. O'Gara J.P. ica and beyond: biofilm mechanisms and regulation in Staphylococcus epidermidis and Staphylococcus aureus. FEMS Microbiol. Lett. 2007, 270:179-188.
68. Peschel A., et al. Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides. J. Biol. Chem. 1999, 274:8405-8410.
69. Collins L.V., et al. Staphylococcus aureus strains lacking D-alanine modifications of teichoic acids are highly susceptible to human neutrophil killing and are virulence attenuated in mice. J. Infect. Dis. 2002, 186:214-219.
70. Staubitz P., et al. MprF-mediated biosynthesis of lysylphosphatidylglycerol, an important determinant in staphylococcal defensin resistance. FEMS Microbiol. Lett. 2004, 231:67-71.
71. Nishi H., et al. Reduced content of lysyl-phosphatidylglycerol in the cytoplasmic membrane affects susceptibility to moenomycin, as well as vancomycin, gentamicin, and antimicrobial peptides, in Staphylococcus aureus. Antimicrob. Agents Chemother. 2004, 48:4800-4807.
72. Weidenmaier C., et al. DltABCD- and MprF-mediated cell envelope modifications of Staphylococcus aureus confer resistance to platelet microbicidal proteins and contribute to virulence in a rabbit endocarditis model. Infect. Immun. 2005, 73:8033-8038.
73. Selsted M.E., et al. Purification, primary structures, and antibacterial activities of beta-defensins, a new family of antimicrobial peptides from bovine neutrophils. J. Biol. Chem. 1993, 268:6641.
74. Sieprawska-Lupa M., et al. Degradation of human antimicrobial peptide LL-37 by Staphylococcus aureus-derived proteinases. Antimicrob. Agents Chemother. 2004, 48:4673-4679.
75. Postma B., et al. Chemotaxis inhibitory protein of Staphylococcus aureus binds specifically to the C5a and formylated peptide receptor. J. Immunol. 2004, 172:6994-7001.
76. Haggar A., et al. The extracellular adherence protein from Staphylococcus aureus inhibits neutrophil binding to endothelial cells. Infect. Immun. 2004, 72:6164-6167.
77. Rooijakkers S.H., van Kessel K.P., van Strijp J.A. Staphylococcal innate immune evasion. Trends Microbiol. 2005, 13:596-601.
78. Rooijakkers S.H., et al. Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases. Nat. Immunol. 2005, 6:920-927.
79. Palmqvist N., et al. Expression of staphylococcal clumping factor A impedes macrophage phagocytosis. Microbes Infect. 2004, 6:188-195.
80. Higgins J., et al. Clumping factor A of Staphylococcus aureus inhibits phagocytosis by human polymorphonuclear leucocytes. FEMS Microbiol. Lett. 2006, 258:290-296.
81. Hammel M., et al. A structural basis for complement inhibition by Staphylococcus aureus. Nat. Immunol. 2007, 8:430-437.
82. Jin T., et al. Staphylococcus aureus resists human defensins by production of staphylokinase, a novel bacterial evasion mechanism. J. Immunol. 2004, 172:1169-1176.
83. Foster T.J. Immune evasion by staphylococci. Nat. Rev. Microbiol. 2005, 3:948-958.
84. Palmqvist N., et al. Protein A is a virulence factor in Staphylococcus aureus arthritis and septic death. Microb. Pathog. 2002, 33:239-249.
85. Thakker M., et al. Staphylococcus aureus serotype 5 capsular polysaccharide is antiphagocytic and enhances bacterial virulence in a murine bacteremia model. Infect. Immun. 1998, 66:5183-5189.
86. Luong T.T., Lee C.Y. Overproduction of type 8 capsular polysaccharide augments Staphylococcus aureus virulence. Infect. Immun. 2002, 70:3389-3395.
87. Kropec A., et al. Poly-N-acetylglucosamine production in Staphylococcus aureus is essential for virulence in murine models of systemic infection. Infect. Immun. 2005, 73:6868-6876.
88. Mandell G.L. Catalase, superoxide dismutase, and virulence of Staphylococcus aureus: in vitro and in vivo studies with emphasis on staphylococcal-leukocyte interaction. J. Clin. Invest. 1975, 55:561-566.
89. Liu G.Y., et al. Staphylococcus aureus golden pigment impairs neutrophil killing and promotes virulence through its antioxidant activity. J. Exp. Med. 2005, 202:209-215.
90. Clauditz A., et al. Staphyloxanthin plays a role in the fitness of Staphylococcus aureus and its ability to cope with oxidative stress. Infect. Immun. 2006, 74:4950-4953.
91. Karavolos M.H., et al. Role and regulation of the superoxide dismutases of Staphylococcus aureus. Microbiology 2003, 149:2749-2758.
92. Gouaux J.E., et al. Subunit stoichiometry of staphylococcal alpha-hemolysin in crystals and on membranes: a heptameric transmembrane pore. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:12828.
93. Bhakdi S., Tranum-Jensen J. Alpha-toxin of Staphylococcus aureus. Microbiol. Rev. 1991, 55:733.
94. Suttorp N., et al. Pore-forming bacterial toxins potently induce release of nitric oxide in porcine endothelial cells. J. Exp. Med. 1993, 178:337.
95. Jonas D., et al. Novel path to apoptosis: small transmembrane pores created by staphylococcal alpha-toxin in T lymphocytes evoke internucleosomal DNA degradation. Infect. Immun. 1994, 62:1304.
96. Jarry T.M., Memmi G., Cheung A.L. The expression of alpha-haemolysin is required for Staphylococcus aureus phagosomal escape after internalization in CFT-1 cells. Cell. Microbiol. 2008, 10:1801-1814.
97. Bubeck Wardenburg J., et al. Poring over pores: alpha-hemolysin and Panton-Valentine leukocidin in Staphylococcus aureus pneumonia. Nat. Med. 2007, 13:1405-1406.
98. Bubeck Wardenburg J., Schneewind O. Vaccine protection against Staphylococcus aureus pneumonia. J. Exp. Med. 2008, 205:287-294.
99. Kaneko J., Kamio Y. Bacterial two-component and hetero-heptameric pore-forming cytolytic toxins: structures, pore-forming mechanism, and organization of the genes. Biosci. Biotechnol. Biochem. 2004, 68:981-1003.
100. Gillet Y., et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 2002, 359:753-759.
101. Labandeira-Rey M., et al. Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia. Science 2007, 315:1130-1133.
102. Villaruz A.E., et al. A point mutation in the agr locus rather than expression of the Panton-Valentine leukocidin caused previously reported phenotypes in Staphylococcus aureus pneumonia and gene regulation. J. Infect. Dis. 2009, 200:724-734.
103. Bubeck Wardenburg J., et al. Panton-Valentine leukocidin is not a virulence determinant in murine models of community-associated methicillin-resistant Staphylococcus aureus disease. J. Infect. Dis. 2008, 198:1166-1170.
104. Tseng C.W., et al. Staphylococcus aureus Panton-Valentine leukocidin contributes to inflammation and muscle tissue injury. PLoS One 2009, 4:e6387.
105. Wadstrom T., Mollby R. Studies on extracellular proteins from Staphylococcus aureus. VII. Studies on beta-hemolysin. Biochim. Biophys. Acta 1972, 242:308.
106. Hayashida A., et al. Staphylococcus aureus beta-toxin induces lung injury through syndecan-1. Am. J. Pathol. 2009, 174:509-518.
107. Diep B.A., Otto M. The role of virulence determinants in community-associated MRSA pathogenesis. Trends Microbiol. 2008, 16:361-369.
108. Wang R., et al. Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat. Med. 2007, 13:1510-1514.
109. Fraser J.D., Proft T. The bacterial superantigen and superantigen-like proteins. Immunol. Rev. 2008, 225:226-243.
110. Nishifuji K., Sugai M., Amagai M. Staphylococcal exfoliative toxins: "molecular scissors" of bacteria that attack the cutaneous defense barrier in mammals. J. Dermatol. Sci. 2008, 49:21-31.
111. Plano L.R. Staphylococcus aureus exfoliative toxins: how they cause disease. J. Invest. Dermatol. 2004, 122:1070-1077.
112. Bjorklind A., Arvidson S. Mutants of Staphylococcus aureus affected in the regulation of exoprotein synthesis. FEMS Microbiol. Lett. 1980, 7:203.
113. Novick R.P. Autoinduction and signal transduction in the regulation of staphylococcal virulence. Mol. Microbiol. 2003, 48:1429.
114. Novick R.P., Geisinger E. Quorum sensing in staphylococci. Annu. Rev. Genet. 2008, 42:541-564.
115. Abdelnour A., et al. The accessory gene regulator (agr) controls Staphylococcus aureus virulence in a murine arthritis model. Infect. Immun. 1993, 61:3879-3885.
116. Rogers K.L., Fey P.D., Rupp M.E. Coagulase-negative staphylococcal infections. Infect. Dis. Clin. North. Am. 2009, 23:73-98.
117. Otto M. Virulence factors of the coagulase-negative staphylococci. Front. Biosci. 2004, 9:841-863.
118. Ludwicka A., et al. Microbial colonization of prosthetic devices. V. Attachment of coagulase-negative staphylococci and "slime"-production on chemically pure synthetic polymers. Zentralbl. Bakteriol. Mikrobiol. Hyg. B 1983, 177:527-532.
119. Gristina A. Biomaterial-centered infection: microbial adhesion versus tissue integration. 1987. Clin. Orthop. Relat. Res. 2004, (427):4-12.
120. Kristinsson K.G. Adherence of staphylococci to intravascular catheters. J. Med. Microbiol. 1989, 28:249-257.
121. Heilman C., et al. Evidence for autolysin-mediated primary attachment of Staphylococcus epidermidis to a polystyrene surface. Mol. Microbiol. 1997, 24:1013.
122. Rupp M.E., et al. Characterization of the importance of Staphylococcus epidermidis autolysin and polysaccharide intercellular adhesin in the pathogenesis of intravascular catheter-associated infection in a rat model. J. Infect. Dis. 2001, 183:1038.
123. Timmerman C.P., et al. Characterization of a proteinaceous adhesion of Staphylococcus epidermidis which mediates attachment to polystyrene. Infect. Immun. 1991, 59:4187.
124. McCrea K.W., et al. The serine-aspartate repeat (Sdr) protein family in Staphylococcus epidermidis. Microbiology 2000, 146:1535.
125. Pei L., Flock J.I. Lack of fbe, the gene for a fibrinogen-binding protein from Staphylococcus epidermidis, reduces its adherence to fibrinogen coated surfaces. Microb. Pathog. 2001, 31:185.
126. Nilsson M., et al. A fibrinogen-binding protein of Staphylococcus epidermidis. Infect. Immun. 1998, 66:2666.
127. Hussain M., et al. Teichoic acid enhances adhesion of Staphylococcus epidermidis to immobilized fibronectin. Microb. Pathog. 2001, 31:261.
128. Bowden M.G., et al. Is the GehD lipase from Staphylococcus epidermidis a collagen binding adhesin?. J. Biol. Chem. 2002, 277:43017-43023.
129. Hall R.T., et al. Characteristics of coagulase-negative staphylococci from infants with bacteremia. Pediatr. Infect. Dis. J. 1987, 6:377.
130. Gruskay J.A., et al. Predicting the pathogenicity of coagulase-negative Staphylococcus in the neonate: slime production, antibiotic resistance, and predominance of Staphylococcus epidermidis species. Pediatrics 1986, 20:397A.
131. Mack D., et al. Characterization of transposon mutants of biofilm-producing Staphylococcus epidermidis impaired in the accumulative phase of biofilm production: genetic identification of a hexosamine-containing polysaccharide intercellular adhesion. Infect. Immun. 1994, 62:3244.
132. Rohde H., et al. Structure, function and contribution of polysaccharide intercellular adhesin (PIA) to Staphylococcus epidermidis biofilm formation and pathogenesis of biomaterial-associated infections. Eur. J. Cell. Biol. 2010, 89:103-111.
133. McKenney D., et al. The ica locus of Staphylococcus epidermidis encodes production of the capsular polysaccharide/adhesin. Infect. Immun. 1998, 66:4711.
134. Galdbart J.O., et al. Screening for Staphylococcus epidermidis markers discriminating between skin-flora strains and those responsible for infections of joint prostheses. J. Infect. Dis. 2000, 182:351-355.
135. Ziebuhr W., et al. A novel mechanism of phase variation of virulence in Staphylococcus epidermidis: evidence for control of the polysaccharide intercellular adhesin synthesis by alternating insertion and excision of the insertion sequence element IS256. Mol. Microbiol. 1999, 32:345.
136. Hussain M., et al. A 140-kilodalton extracellular protein is essential for the accumulation of Staphylococcus epidermidis strains on surfaces. Infect. Immun. 1997, 65:519.
137. Kocianova S., et al. Key role of poly-gamma-DL-glutamic acid in immune evasion and virulence of Staphylococcus epidermidis. J. Clin. Invest. 2005, 115:688-694.
138. Vuong C., Götz F., Otto M. Construction and characterization of an agr deletion mutant of Staphylococcus epidermidis. Infect. Immun. 2000, 68:1048.
139. Kristian S.A., et al. Biofilm formation induces C3a release and protects Staphylococcus epidermidis from IgG and complement deposition and from neutrophil-dependent killing. J. Infect. Dis. 2008, 197:1028-1035.
140. Farber B.F., Kaplan M.H., Clogston A.G. Staphylococcus epidermidis extracted slime inhibits the antimicrobial action of glycopeptide antibodies. J. Infect. Dis. 1990, 161:37.
141. Kristinsson K.G., Spencer R.C. Slime production as a marker for clinically significant infection with coagulase-negative staphylococci. J. Infect. Dis. 1986, 154:728.
142. Younger J.J., et al. Coagulase-negative staphylococci isolated from cerebrospinal fluid shunts: importance of slime production, species identification, and shunt removal to clinical outcome. J. Infect. Dis. 1987, 156:548.
143. Ohara-Nemoto Y., et al. Characterization and molecular cloning of a glutamyl endopeptidase from Staphylococcus epidermidis. Microb. Pathog. 2002, 33:33-41.
144. Liles W.C., et al. Stimulation of human neutrophils and monocytes by staphylococcal phenol-soluble modulin. J. Leukoc. Biol. 2001, 70:96-102.
145. Koenig J.M., Yoder M.C. Neonatal neutrophils: the good, the bad, and the ugly. Clin. Perinatol. 2004, 31:39-51.
146. Mease A.D. Tissue neutropenia: the newborn neutrophil in perspective. J. Perinatol. 1990, 10:55.
147. Anderson D.C., Hughes B., Smith C.W. Abnormality motility of neonatal polymorphonuclear leukocytes. J. Clin. Invest. 1981, 68:863.
148. Schibler K.R., et al. Diminished transcription of interleukin-8 by monocytes from preterm neonates. J. Leukoc. Biol. 1993, 53:399.
149. Yoshimura T.K., et al. Purification of a human monocyte derived neutrophil chemotactic factor that shares sequence homology with other host defense cytokinase. Proc. Natl. Acad. Sci. U. S. A. 1987, 84:9233.
150. Zimmerman G.A., Prescott S.M., McIntyre T.M. Endothelial cell, interactions with granulocytes: tethering and signaling molecules. Immunol. Today 1992, 13:93.
151. Shigeoka A.O., et al. Defective oxidative metabolic responses of neutrophils from stressed infants. J. Pediatr. 1981, 98:392.
152. Strauss R.G., Snyder E.L. Activation and activity of the superoxide-generating system of neutrophils from human infants. Pediatr. Res. 1983, 17:662.
153. Herman T.E., Siegel M.J. Chronic granulomatous disease of childhood: neonatal serratia, hepatic abscesses, and pulmonary aspergillosis. J. Perinatol. 2002, 22:255-256.
154. Banffer J.R.J., Franken J.F. Immunization with leucocidin toxoid against staphylococcal infection. Pathol. Microbiol. (Basel) 1967, 30:166.
155. Lack C.H., Towers A.G. Serological tests for staphylococcal infection. BMJ 1962, 2:1227.
156. Florman A.L., et al. Relation of 7S and 19S staphylococcal hemagglutinating antibody to age of individual. Pediatrics 1963, 32:501.
157. Lavoipierre G.J., et al. A vaccine trial for neonatal staphylococcal disease. Am. J. Dis. Child. 1971, 122:377.
158. McLoughlin R.M., et al. CD4+ T cells and CXC chemokines modulate the pathogenesis of Staphylococcus aureus wound infections. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:10408-10413.
159. Marrach P., Kappler J. The staphylococcal enterotoxin and their relatives. Science 1990, 248:705.
160. Eichenwald H.F., Shinefield H.R. The problem of staphylococcal infection in newborn infants. J. Pediatr. 1960, 56:665-674.
161. Sohn A.H., et al. Prevalence of nosocomial infections in neonatal intensive care unit patients: results from the first national point-prevalence survey. J. Pediatr. 2001, 139:821-827.
162. Isaacs D. A ten year, multicentre study of coagulase negative staphylococcal infections in Australasian neonatal units. Arch. Dis. Child. Fetal Neonatal Ed. 2003, 88:F89-F93.
163. Isaacs D., Fraser S., Hogg G., et al. Staphylococcus aureus infections in Australasian neonatal nurseries. Arch. Dis. Child. Fetal Neonatal Ed. 2004, 89:F331-F335.
164. Chapman R.L., Faix R.G. Persistent bacteremia and outcome in late onset infection among infants in a neonatal intensive care unit. Pediatr. Infect. Dis. J. 2003, 22:17-21.
165. Benjamin D.K., et al. Mortality following blood culture in premature infants: increased with Gram-negative bacteremia and candidemia, but not Gram-positive bacteremia. J. Perinatol. 2004, 24:175-180.
166. Ronnestad A., et al. Septicemia in the first week of life in a Norwegian national cohort of extremely premature infants. Pediatrics 2005, 115:e262-e268.
167. Stoll B.J., et al. Very low birth weight preterm infants with early onset neonatal sepsis: the predominance of gram-negative infections continues in the National Institute of Child Health and Human Development Neonatal Research Network, 2002-2003. Pediatr. Infect. Dis. J. 2005, 24:635-639.
168. Regev-Yochay G., et al. Methicillin-resistant Staphylococcus aureus in neonatal intensive care unit. Emerg. Infect. Dis. 2005, 11:453-456.
169. Huang Y.C., et al. Methicillin-resistant Staphylococcus aureus colonization and its association with infection among infants hospitalized in neonatal intensive care units. Pediatrics 2006, 118:469-474.
170. Khashu M., et al. Persistent bacteremia and severe thrombocytopenia caused by coagulase-negative Staphylococcus in a neonatal intensive care unit. Pediatrics 2006, 117:340-348.
171. Gomez-Gonzalez C., et al. Long persistence of methicillin-susceptible strains of Staphylococcus aureus causing sepsis in a neonatal intensive care unit. J. Clin. Microbiol. 2007, 45:2301-2304.
172. Kuint J., et al. Comparison of community-acquired methicillin-resistant Staphylococcus aureus bacteremia to other staphylococcal species in a neonatal intensive care unit. Eur. J. Pediatr. 2007, 166:319-325.
173. Hira V., et al. Clinical and molecular epidemiologic characteristics of coagulase-negative staphylococcal bloodstream infections in intensive care neonates. Pediatr. Infect. Dis. J. 2007, 26:607-612.
174. Seybold U., et al. Emergence of and risk factors for methicillin-resistant Staphylococcus aureus of community origin in intensive care nurseries. Pediatrics 2008, 122:1039-1046.
175. Carey A.J., Saiman L., Polin R.A. Hospital-acquired infections in the NICU: epidemiology for the new millennium. Clin. Perinatol. 2008, 35:223-249.
176. Palazzi D.L., Klein J.O., Baker C.J. Bacterial sepsis and meningitis. Infectious Diseases of the Fetus and Newborn Infant 2006, 247-296. Saunders, Philadelphia. sixth ed. J.S. Remington (Ed.).
177. Vesikari T., et al. Neonatal septicaemia. Arch. Dis. Child. 1985, 60:542-546.
178. Healy C.M., et al. Features of invasive staphylococcal disease in neonates. Pediatrics 2004, 114:953-961.
179. Healy C.M., et al. Emergence of new strains of methicillin-resistant Staphylococcus aureus in a neonatal intensive care unit. Clin. Infect. Dis. 2004, 39:1460-1466.
180. Chuang Y.Y., et al. Methicillin-resistant Staphylococcus aureus bacteraemia in neonatal intensive care units: an analysis of 90 episodes. Acta Paediatr. 2004, 93:786-790.
181. Cohen-Wolkowiez M., et al. Mortality and neurodevelopmental outcome after Staphylococcus aureus bacteremia in infants. Pediatr. Infect. Dis. J. 2007, 26:1159-1161.
182. Sanghvi K.P., Tudehope D.I. Neonatal bacterial sepsis in a neonatal intensive care unit: a 5 year analysis. J. Paediatr. Child Health 1996, 32:333.
183. Beck-Sague C.M., et al. Bloodstream infections in neonatal intensive care unit patients: results of a multicenter study. Pediatr. Infect. Dis. J. 1994, 13:1110.
184. Edwards J.R., et al. National Healthcare Safety Network (NHSN) Report, data summary for 2006 through 2007, issued November 2008. Am. J. Infect. Control. 2008, 36:609-626.
185. Kilbride H.W., et al. Evaluation and development of potentially better practices to prevent neonatal nosocomial bacteremia. Pediatrics 2003, 111:e504-e518.
186. Fanaroff A.A., et al. Incidence, presenting features, risk factors and significance of late onset septicemia in very low birth weight infants. The National Institute of Child Health and Human Development Neonatal Research Network. Pediatr. Infect. Dis. J. 1998, 17:593-598.
187. Makhoul I.R., et al. Pathogen-specific early mortality in very low birth weight infants with late-onset sepsis: a national survey. Clin. Infect. Dis. 2005, 40:218-224.
188. Karlowicz M.G., et al. Central venous catheter removal versus in situ treatment in neonates with coagulase-negative staphylococcal bacteremia. Pediatr. Infect. Dis. J. 2002, 21:22-27.
189. Benjamin D.K., et al. Bacteremia, central catheters, and neonates: when to pull the line. Pediatrics 2001, 107:1272-1276.
190. Lawrence S.L., et al. Cloxacillin versus vancomycin for presumed late-onset sepsis in the Neonatal Intensive Care Unit and the impact upon outcome of coagulase negative staphylococcal bacteremia: a retrospective cohort study. BMC Pediatr. 2005, 5:49.
191. Powell C., Bubb S., Clark J. Toxic shock syndrome in a neonate. Pediatr. Infect. Dis. J. 2007, 26:759-760.
192. Kikuchi K., et al. Molecular epidemiology of methicillin-resistant Staphylococcus aureus strains causing neonatal toxic shock syndrome-like exanthematous disease in neonatal and perinatal wards. J. Clin. Microbiol. 2003, 41:3001-3006.
193. Schlievert P.M. Alteration of immune function by staphylococcal pyrogenic exotoxin type C: possible role in toxic-shock syndrome. J. Infect. Dis. 1983, 147:391.
194. Schlievert P.M. Staphylococcal enterotoxin B and toxic-shock syndrome toxin-1 are significantly associated with non-menstrual TSS. Lancet 1986, 1:1149.
195. Takahashi N., Nishida H. New exanthematous disease with thrombocytopenia in neonates. Arch. Dis. Child. Fetal Neonatal Ed. 1997, 77:F79.
196. Takahashi N., et al. Exanthematous disease induced by toxic shock syndrome toxin 1 in the early neonatal period. Lancet 1998, 351:1614.
197. Takahashi N., et al. Immunopathophysiological aspects of an emerging neonatal infectious disease induced by a bacterial superantigen. J. Clin. Invest. 2000, 106:1409.
198. Symchych P.S., Krauss A.N., Winchester P. Endocarditis following intracardiac placement of umbilical venous catheters in neonates. J. Pediatr. 1977, 90:287.
199. Johnson D.H., Rosenthal A., Nadas A.S. A forty-year review of bacterial endocarditis in infancy and childhood. Circulation 1975, 51:581.
200. Millard D.D., Shulman S.T. The changing spectrum of neonatal endocarditis. Clin. Perinatol. 1988, 15:587.
201. Mecrow I.K., Ladusans E.J. Infective endocarditis in newborn infants with structurally normal hearts. Acta Paediatr. 1994, 83:35.
202. Daher A.H., Berkowitz F.E. Infective endocarditis in neonates. Clin.
203. Pearlman S.A., et al. Infective endocarditis in the premature neonate. Clin. Pediatr. (Phila) 1998, 37:741.
204. Opie G.F., et al. Bacterial endocarditis in neonatal intensive care. J. Paediatr. Child Health 1999, 35:545-548.
205. Valente A.M., et al. Frequency of infective endocarditis among infants and children with Staphylococcus aureus bacteremia. Pediatrics 2005, 115:e15-e19.
206. Milazzo A.S., Li J.S. Bacterial endocarditis in infants and children. Pediatr. Infect. Dis. J. 2001, 20:799-801.
207. O'Callaghan C., McDougall P. Infective endocarditis in neonates. Arch. Dis. Child. 1988, 63:53-57.
208. Armstrong D., et al. Staphylococcus aureus endocarditis in preterm neonates. Am. J. Perinatol. 2002, 19:247-251.
209. Sung T.J., Kim H.M., Kim M.J. Methicillin-resistant Staphylococcus aureus endocarditis in an extremely low-birth-weight infant treated with linezolid. Clin. Pediatr. (Phila) 2008, 47:504-506.
210. Fortunov R.M., et al. Community-acquired Staphylococcus aureus infections in term and near-term previously healthy neonates. Pediatrics 2006, 118:874-881.
211. Fortunov R.M., et al. Evaluation and treatment of community-acquired Staphylococcus aureus infections in term and late-preterm previously healthy neonates. Pediatrics 2007, 120:937-945.
212. James L., et al. Methicillin-resistant Staphylococcus aureus infections among healthy full-term newborns. Arch. Dis. Child. Fetal Neonatal Ed. 2008, 93:F40-F44.
213. Nguyen D.M., et al. Risk factors for neonatal methicillin-resistant Staphylococcus aureus infection in a well-infant nursery. Infect. Control. Hosp. Epidemiol. 2007, 28:406-411.
214. Kim Y.H., et al. Clinical outcomes in methicillin-resistant Staphylococcus aureus-colonized neonates in the neonatal intensive care unit. Neonatology 2007, 91:241-247.
215. Ayliffe G.A., et al. Staphylococcal infection in cervical glands of infants. Lancet 1972, 2:479.
216. Dewar J., Porter I.A., Smylie G.H. Staphylococcal infection in cervical glands of infants. Lancet 1972, 2:712.
217. Sabatino G., et al. Neonatal suppurative parotitis: a study of five cases. Eur. J. Pediatr. 1999, 158:312.
218. Spiegel R., et al. Acute neonatal suppurative parotitis: case reports and review. Pediatr. Infect. Dis. J. 2004, 23:76.
219. Raad I.I., Sabbagh M.F., Caranasos G.J. Acute bacterial sialadenitis: a study of 29 cases and review. Rev. Infect. Dis. 1990, 12:591.
220. David R.B., O'Connel E.J. Suppurative parotitis in children. Am. J. Dis. Child. 1970, 119:332.
221. Rudoy R.C., Nelson J.D. Breast abscess during the neonatal period: a review. Am. J. Dis. Child. 1975, 129:1031-1034.
222. Kalwbow H. Über Mastitis neonatorum und ihre Folgen. Zentralbl. Gynakol. 1936, 60:1821.
223. Bodemer C., et al. Staphylococcal necrotizing fasciitis in the mammary region in childhood: a report of five cases. J. Pediatr. 1997, 131:466-469.
224. Sawardekar K.P. Changing spectrum of neonatal omphalitis. Pediatr. Infect. Dis. J. 2004, 23:22-26.
225. Mason W.H., et al. Omphalitis in the newborn infant. Pediatr. Infect. Dis. J. 1989, 8:521-525.
226. Lally K.P., et al. Necrotizing fasciitis: a serious sequela of omphalitis in the newborn. Ann. Surg. 1984, 199:101-103.
227. Samuel M., et al. Necrotizing fasciitis: a serious complication of omphalitis in neonates. J. Pediatr. Surg. 1994, 29:1414-1416.
228. Hsieh W.S., et al. Neonatal necrotizing fasciitis: a report of three cases and review of the literature. Pediatrics 1999, 103:e53.
229. Miller L.G., et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N. Engl. J. Med. 2005, 352:1445-1453.
230. Dehority W., et al. Community-associated methicillin-resistant Staphylococcus aureus necrotizing fasciitis in a neonate. Pediatr. Infect. Dis. J. 2006, 25:1080-1081.
231. Hayani K.C., et al. Neonatal necrotizing fasciitis due to community-acquired methicillin resistant Staphylococcus aureus. Pediatr. Infect. Dis. J. 2008, 27:480-481.
232. Yu J.S., Habib P. MR imaging of urgent inflammatory and infectious conditions affecting the soft tissues of the musculoskeletal system. Emerg. Radiol. 2009, 16:267-276.
233. Edlich R.F., et al. Modern concepts of the diagnosis and treatment of necrotizing fasciitis. J. Emerg. Med. 2008, in press.
234. Brown D.R., et al. A multicenter review of the treatment of major truncal necrotizing infections with and without hyperbaric oxygen therapy. Am. J. Surg. 1994, 167:485-489.
235. Kapoor V., Travadi J., Braye S. Staphylococcal scalded skin syndrome in an extremely premature neonate: a case report with a brief review of literature. J. Paediatr. Child Health 2008, 44:374-376.
236. Makhoul I.R., et al. Staphylococcal scalded-skin syndrome in a very low birth weight premature infant. Pediatrics 2001, 108:E16.
237. Peters B., et al. Staphylococcal scalded-skin syndrome complicating wound infection in a preterm infant with postoperative chylothorax. J. Clin. Microbiol. 1998, 36:3057-3059.
238. Rieger-Fackeldey E., et al. Staphylococcal scalded skin syndrome related to an exfoliative toxin A- and B-producing strain in preterm infants. Eur. J. Pediatr. 2002, 161:649-652.
239. Curran J.P., Al-Salihi F.L. Neonatal staphylococcal scalded skin syndrome: massive outbreak due to an unusual phage type. Pediatrics 1980, 66:285-290.
240. Ritter von Rittershain G. Die exfoliative Dermatitis jüngerer Säuglinge. Zentralztg. Kinderheilkd. 1878, 2:3-23.
241. Melish M.E., Glasgow L.A. Staphylococcal scalded skin syndrome: the expanded clinical syndrome. J. Pediatr. 1971, 78:958-967.
242. Farrell A.M. Staphylococcal scalded-skin syndrome. Lancet 1999, 354:880-881.
243. Hoffmann R., et al. Staphylococcal scalded skin syndrome (SSSS) and consecutive septicaemia in a preterm infant. Pathol. Res. Pract. 1994, 190:77-81.
244. Lo W.T., Wang C.C., Chu M.L. Intrauterine staphylococcal scalded skin syndrome: report of a case. Pediatr. Infect. Dis. J. 2000, 19:481-482.
245. Loughead J.L. Congenital staphylococcal scaled skin syndrome: report of a case. Pediatr. Infect. Dis. J. 1992, 11:413-414.
246. Haveman L.M., et al. Congenital staphylococcal scalded skin syndrome in a premature infant. Acta Paediatr. 2004, 93:1661-1662.
247. Dancer S.J., et al. Outbreak of staphylococcal scalded skin syndrome among neonates. J. Infect. 1988, 16:87-103.
248. Beaven D.W., Burry A.F. Staphylococcal pneumonia in the newborn: an epidemic with 8 fatal cases. Lancet 1956, 271:211-215.
249. Shinefield H.R., Ruff N.L. Staphylococcal infections: a historical perspective. Infect. Dis. Clin. North Am. 2009, 23:1-15.
250. Yee-Guardino S., et al. Recognition and treatment of neonatal community-associated MRSA pneumonia and bacteremia. Pediatr. Pulmonol. 2008, 43:203-205.
251. Drinkovic D., et al. Neonatal coagulase-negative staphylococcal meningitis: a report of two cases. Pathology 2002, 34:586-588.
252. de Oliveira R.S., et al. Brain abscess in a neonate: an unusual presentation. Childs Nerv. Syst. 2007, 23:139-142.
253. Regev R.H., Dolfin T.Z., Zamir C. Multiple brain abscesses in a premature infant: complication of Staphylococcus aureus sepsis. Acta Paediatr. 1995, 84:585-587.
254. Vartzelis G., et al. Brain abscesses complicating Staphylococcus aureus sepsis in a premature infant. Infection 2005, 33:36-38.
255. Vinchon M., Dhellemmes P. Cerebrospinal fluid shunt infection: risk factors and long-term follow-up. Childs Nerv. Syst. 2006, 22:692-697.
256. Reinprecht A., et al. Posthemorrhagic hydrocephalus in preterm infants: long-term follow-up and shunt-related complications. Childs Nerv. Syst. 2001, 17:663-669.
257. Anderson E.J., Yogev R. A rational approach to the management of ventricular shunt infections. Pediatr. Infect. Dis. J. 2005, 24:557-558.
258. Sciubba D.M., et al. Antibiotic-impregnated shunt catheters for the treatment of infantile hydrocephalus. Pediatr. Neurosurg. 2008, 44:91-96.
259. Filka J., et al. Nosocomial meningitis in children after ventriculoperitoneal shunt insertion. Acta Paediatr. 1999, 88:576-578.
260. James H.E., Bradley J.S. Aggressive management of shunt infection: combined intravenous and intraventricular antibiotic therapy for twelve or less days. Pediatr. Neurosurg. 2008, 44:104-111.
261. Nava-Ocampo A.A., et al. Antimicrobial therapy and local toxicity of intraventricular administration of vancomycin in a neonate with ventriculitis. Ther. Drug Monit. 2006, 28:474-476.
262. Cook A.M., et al. Linezolid for the treatment of a heteroresistant Staphylococcus aureus shunt infection. Pediatr. Neurosurg. 2005, 41:102-104.
263. Potter C.M. Osteomyelitis in the newborn. J. Bone Joint Surg. Br. 1954, 36:578-583.
264. Walsh S.Z., Craig J.D. Generalized osteomyelitis in a newborn infant. J. Pediatr. 1958, 52:313-318.
265. Bergdahl S., Ekengren K., Eriksson M. Neonatal hematogenous osteomyelitis: risk factors for long-term sequelae. J. Pediatr. Orthop. 1985, 5:564-568.
266. Frederiksen B., Christiansen P., Knudsen F.U. Acute osteomyelitis and septic arthritis in the neonate, risk factors and outcome. Eur. J. Pediatr. 1993, 152:577-580.
267. Williamson J.B., Galasko C.S., Robinson M.J. Outcome after acute osteomyelitis in preterm infants. Arch. Dis. Child. 1990, 65:1060-1062.
268. Wong M., et al. Clinical and diagnostic features of osteomyelitis occurring in the first three months of life. Pediatr. Infect. Dis. J. 1995, 14:1047-1053.
269. Ogden J.A. Pediatric osteomyelitis and septic arthritis: the pathology of neonatal disease. Yale J. Biol. Med. 1979, 52:423-448.
270. Ogden J.A., Lister G. The pathology of neonatal osteomyelitis. Pediatrics 1975, 55:474-478.
271. Offiah A.C. Acute osteomyelitis, septic arthritis and discitis: differences between neonates and older children. Eur. J. Radiol. 2006, 60:221-232.
272. Korakaki E., et al. Methicillin-resistant Staphylococcus aureus osteomyelitis and septic arthritis in neonates: diagnosis and management. Jpn. J. Infect. Dis. 2007, 60:129-131.
273. Waseem M., Devas G., Laureta E. A neonate with asymmetric arm movements. Pediatr. Emerg. Care 2009, 25:98-99.
274. Parmar J. Case report: septic arthritis of the temporomandibular joint in a neonate. Br. J. Oral. Maxillofac. Surg. 2008, 46:505-506.
275. Lim M.O., et al. Osteomyelitis as a complication of umbilical artery catheterization. Am. J. Dis. Child. 1977, 131:142-144.
276. Lilien L.D., et al. Neonatal osteomyelitis of the calcaneus: complication of heel puncture. J. Pediatr. 1976, 88:478-480.
277. Yuksel S., et al. Osteomyelitis of the calcaneus in the newborn: an ongoing complication of Guthrie test. Eur. J. Pediatr. 2007, 166:503-504.
278. Overturf G.D., Balfour G. Osteomyelitis and sepsis: severe complications of fetal monitoring. Pediatrics 1975, 55:244-247.
279. Asnes R.S., Arendar G.M. Septic arthritis of the hip: a complication of femoral venipuncture. Pediatrics 1966, 38:837-841.
280. Barrie D. Staphylococcal colonization of the rectum in the newborn. BMJ 1966, 1:1574-1576.
281. Ottenheimer E.J., et al. Studies of the epidemiology of staphylococcal infection. Bull. Johns Hopkins Hosp. 1961, 109:114.
282. Christie C.D., Lynch-Ballard E., Andiman W.A. Staphylococcal enterocolitis revisited: cytotoxic properties of Staphylococcus aureus from a neonate with enterocolitis. Pediatr. Infect. Dis. J. 1988, 7:791-795.
283. Gutman L.T., et al. Neonatal staphylococcal enterocolitis: association with indwelling feeding catheters and S. aureus colonization. J. Pediatr. 1976, 88:836-839.
284. Masunaga K., et al. Colonic stenosis after severe methicillin-resistant Staphylococcus aureus enterocolitis in a newborn. Pediatr. Infect. Dis. J. 1999, 18:169-171.
285. Scheifele D.W., et al. Delta-like toxin produced by coagulase-negative staphylococci is associated with neonatal necrotizing enterocolitis. Infect. Immun. 1987, 55:2268-2273.
286. Overturf G.D., et al. Neonatal necrotizing enterocolitis associated with delta toxin-producing methicillin-resistant Staphylococcus aureus. Pediatr. Infect. Dis. J. 1990, 9:88-91.
287. Mehr S., Doyle L.W. Cytokines as markers of bacterial sepsis in newborn infants: a review. Pediatr. Infect. Dis. J. 2000, 19:879-887.
288. Mishra U.K., et al. Newer approaches to the diagnosis of early onset neonatal sepsis. Arch. Dis. Child. Fetal Neonatal Ed. 2006, 91:F208-F212.
289. Makhoul I.R., et al. Values of C-reactive protein, procalcitonin, and Staphylococcus-specific PCR in neonatal late-onset sepsis. Acta Paediatr. 2006, 95:1218-1223.
290. Vazzalwar R., et al. Procalcitonin as a screening test for late-onset sepsis in preterm very low birth weight infants. J. Perinatol. 2005, 25:397-402.
291. Sherwin C., et al. Utility of interleukin-12 and interleukin-10 in comparison with other cytokines and acute-phase reactants in the diagnosis of neonatal sepsis. Am. J. Perinatol. 2008, 25:629-636.
292. Harris M.C., et al. Cytokine elaboration in critically ill infants with bacterial sepsis, necrotizing enterocolitis, or sepsis syndrome: correlation with clinical parameters of inflammation and mortality. J. Pediatr. 2005, 147:462-468.
293. Lam H.S., Ng P.C. Biochemical markers of neonatal sepsis. Pathology 2008, 40:141-148.
294. Lopez Sastre J.B., et al. Procalcitonin is not sufficiently reliable to be the sole marker of neonatal sepsis of nosocomial origin. BMC Pediatr. 2006, 6:16.
295. Patrick C.C., et al. Persistent bacteremia due to coagulase-negative staphylococci in low birthweight neonates. Pediatrics 1989, 84:977.
296. Baumgart S., et al. Sepsis with coagulase-negative staphylococci in critically ill newborns. Am. J. Dis. Child. 1983, 137:461.
297. Schmidt B.K., et al. Coagulase-negative staphylococci as true pathogens in newborn infants: a cohort study. Pediatr. Infect. Dis. J. 1987, 6:1026.
298. Ohlin A., et al. Real-time PCR of the 16S-rRNA gene in the diagnosis of neonatal bacteraemia. Acta Paediatr. 2008, 97:1376-1380.
299. Rybak M., et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am. J. Health Syst. Pharm. 2009, 66:82-98.
300. Capparelli E.V., et al. The influences of renal function and maturation on vancomycin elimination in newborns and infants. J. Clin. Pharmacol. 2001, 41:927-934.
301. Reiter P.D., Doron M.W. Vancomycin cerebrospinal fluid concentrations after intravenous administration in premature infants. J. Perinatol. 1996, 16:331-335.
302. de Hoog M., Mouton J.W., van den Anker J.N. Vancomycin: pharmacokinetics and administration regimens in neonates. Clin. Pharmacokinet. 2004, 43:417-440.
303. Plan O., et al. Continuous-infusion vancomycin therapy for preterm neonates with suspected or documented Gram-positive infections: a new dosage schedule. Arch. Dis. Child. Fetal Neonatal Ed. 2008, 93:F418-F421.
304. Sanchez P., Bradley J.S., Nelson J.D. Antiinfective therapy for newborns. 2008-2009 Nelson's Pocket Book of Pediatric Antimicrobial Therapy 2008, 16-29. American Academy of Pediatrics, Chicago. seventeenth ed. J.S. Bradley, J.D. Nelson (Eds.).
305. Meka V.G., Gold H.S. Antimicrobial resistance to linezolid. Clin. Infect. Dis. 2004, 39:1010-1015.
306. Deville J.G., et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatr. Infect. Dis. J. 2003, 22:S158-S163.
307. Jungbluth G.L., Welshman I.R., Hopkins N.K. Linezolid pharmacokinetics in pediatric patients: an overview. Pediatr. Infect. Dis. J. 2003, 22:S153-S157.
308. Baddour L.M., Wilson W.R., Bayer A.S., et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005, 111:e394-e434.
309. Soraisham A.S., Al-Hindi M.Y. Intravenous rifampicin for persistent staphylococcal bacteremia in premature infants. Pediatr. Int. 2008, 50:124-126.
310. Ohlsson A., Lacy J.B. Intravenous immunoglobulin for suspected or subsequently proven infection in neonates. Cochrane Database Syst. Rev. 2004, CD001239.
311. Andersen B.M., et al. Spread of methicillin-resistant Staphylococcus aureus in a neonatal intensive unit associated with understaffing, overcrowding and mixing of patients. J. Hosp. Infect. 2002, 50:18.
312. Haley R.W., et al. Eradication of endemic methicillin-resistant Staphylococcus aureus infections from a neonatal intensive care unit. J. Infect. Dis. 1995, 171:614.
313. Rountree P.M., et al. Control of staphylococcal infection of newborn by treatment of nasal carriers in staff. Med. J. Aust. 1956, 1:528.
314. Gillespie W.A., Adler V.G. Control of an outbreak of staphylococcal infection in a hospital. Lancet 1957, 1:632.
315. Martin W.J., Nichols D.R., Henderson E.D. The problem of management of nasal carriers of staphylococci. Proc. Mayo Clin. 1960, 35:282.
316. Williams J.D., et al. Trials of five antibacterial creams in the control of nasal carriage of Staphylococcus aureus. Lancet 1967, 2:390.
317. Smith R.T. The role of the chronic carrier in an epidemic of staphylococcal disease in a newborn nursery. Am. J. Dis. Child. 1958, 95:461.
318. Wysham D.N., et al. Staphylococcal infections in an obstetric unit. I. Epidemiologic studies of pyoderma neonatorum. N. Engl. J. Med. 1957, 257:295.
319. Belani A., et al. Outbreak of staphylococcal infection in two hospital nurseries traced to a single nasal carrier. Infect. Control. 1986, 7:487.
320. Garner J.S. Guideline for isolation precautions in hospitals. The Hospital Infection Control Practices Advisory Committee. Infect. Control. Hosp. Epidemiol. 1996, 17:214. [erratum appears in, ], Infect. Control. Hosp. Epidemiol. 17 (1996) 5.
321. Jernigan J.A., et al. Effectiveness of contact isolation during a hospital outbreak of methicillin-resistant Staphylococcus aureus. Am. J. Epidemiol. 1996, 143:496. [erratum appears in Am. J. Epidemiol.].
322. Gerber S.I., et al. Management of outbreaks of methicillin-resistant Staphylococcus aureus infection in the neonatal intensive care unit: a consensus statement. Infect. Control Hosp. Epidemiol. 2006, 27:139-145.
323. Bertin M.L., et al. Outbreak of methicillin-resistant Staphylococcus aureus colonization and infection in a neonatal intensive care unit epidemiologically linked to a healthcare worker with chronic otitis. Infect. Control Hosp. Epidemiol. 2006, 27:581-585.
324. Otter J.A., et al. Identification and control of an outbreak of ciprofloxacin-susceptible EMRSA-15 on a neonatal unit. J. Hosp. Infect. 2007, 67:232-239.
325. McDonald J.R., et al. Methicillin-resistant Staphylococcus aureus outbreak in an intensive care nursery: potential for interinstitutional spread. Pediatr. Infect. Dis. J. 2007, 26:678-683.
326. Shinefield H.R., Ribble J.C., Boris M. Bacterial interference between strains of Staphylococcus aureus, 1960 to 1970. Am. J. Dis. Child. 1971, 121:148.
327. Light I.J., Sutherland J.M., Schott J.E. Control of a staphylococcal outbreak in a nursery-use of bacterial interference. JAMA 1965, 193:699.
328. Shinefield H.R. Bacterial interference. Ann. N. Y. Acad. Sci. 1974, 236:444.
329. Mortimer E.A., et al. Transmission of staphylococci between newborns: importance of the hands of personnel. Am. J. Dis. Child. 1962, 104:289.
330. Kretzer E.K., Larson E.L. Behavioral interventions to improve infection control practices. Am. J. Infect. Control 1998, 26:245.
331. Tibballs J. Teaching hospital medical staff to handwash. Med. J. Aust. 1996, 164:395.
332. Pittet D. Improving compliance with hand hygiene in hospitals. Infect. Control Hosp. Epidemiol. 2000, 21:381.
333. Ehrenkranz N.J., Alfonso B.C. Failure of bland soap handwash to prevent hand transfer of patient bacteria to urethral catheters. Infect. Control Hosp. Epidemiol. 1991, 12:654.
334. Aly H., et al. Is bloodstream infection preventable among premature infants? A tale of two cities. Pediatrics 2005, 115:1513-1518.
335. Durand M., et al. Prospective evaluation of percutaneous central venous Silastic catheters in newborn infants with birth weights of 510 to 3, 920 grams. Pediatrics 1986, 78:245.
336. Lodha A., et al. Prophylactic antibiotics in the prevention of catheter-associated bloodstream bacterial infection in preterm neonates: a systematic review. J. Perinatol. 2008, 28:526-533.
337. Spafford P.S., et al. Prevention of central venous catheter-related coagulase-negative staphylococcal sepsis in neonates. J. Pediatr. 1994, 125:259-263.
338. Cooke R.W., et al. Low-dose vancomycin prophylaxis reduces coagulase-negative staphylococcal bacteraemia in very low birthweight infants. J. Hosp. Infect. 1997, 37:297-303.
339. Garland J.S., et al. A vancomycin-heparin lock solution for prevention of nosocomial bloodstream infection in critically ill neonates with peripherally inserted central venous catheters: a prospective, randomized trial. Pediatrics 2005, 116:e198-e205.
340. Jardine L.A., Inglis G.D., Davies M.W. Prophylactic systemic antibiotics to reduce morbidity and mortality in neonates with central venous catheters. Cochrane Database Syst. Rev. 2008, CD006179.
341. Benjamin D.K., et al. A blinded, randomized, multicenter study of an intravenous Staphylococcus aureus immune globulin. J. Perinatol. 2006, 26:290-295.
342. DeJonge M., et al. Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants. J. Pediatr. 2007, 151:260-265.
343. de la Morena M.T. Specific immune globulin therapy for prevention of nosocomial staphylococcal bloodstream infection in premature infants: not what we hoped for!. J. Pediatr. 2007, 151:232-234.
344. Weisman L.E., Thackray H.M., Cracia-Prats J.A. Phase I/II double blind, placebo controlled, dose escalation, safety and pharmacokinetics study in very low birth weight neonates of BSYX-a110, an anti-staphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections 2004, PAS Late-Breaker Abstract Presentations, San Francisco.
345. Orsi N. The antimicrobial activity of lactoferrin: current status and perspectives. Biometals 2004, 17:189-196.
346. Manzoni P., et al. Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial. JAMA 2009, 302:1421-1428.